VANGL2

Across TCGA pan-cancer cohorts, VANGL2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated VANGL2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher VANGL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VANGL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CESC show a favorable association.

LUSC, DLBC, and HNSC are the cancer types where VANGL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.108	0.746	<.001	36	view →
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
HNSC	DFS	Median	IV	0.164	0.646	<.001	24	view →
KIRC	OS	Median	All	0.133	0.630	.002	18	view →
UCEC	DFS	Median	All	0.945	0.622	.012	12	view →
CESC	DFS	Median	All	1.000	0.517	.028	6	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

VANGL2–LUSC (OS)

Open the LUSC breakdown →